The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant
Open accessAbstract
Relative to several other toll-like receptor (TLR) agonists, we found polyinosinic:polycytidylic acid (poly IC) to be the most effective adjuvant for Th1 CD4+ T cell responses to a dendritic cell (DC)–targeted HIV gag protein vaccine in mice. To identify mechanisms for adjuvant action in the intact animal and the polyclonal T cell repertoire, we found poly IC to be the most effective inducer of type I interferon (IFN), which was produced by DEC-205+ DCs, monocytes, and stromal cells. Antibody blocking or deletion of type I IFN receptor showed that IFN was essential for DC maturation and development of CD4+ immunity. The IFN-AR receptor was directly required for DCs to respond to poly IC. STAT 1 was also essential, in keeping with the type I IFN requirement, but not type II IFN or IL-12 p40. Induction of type I IFN was mda5 dependent, but DCs additionally used TLR3. In bone marrow chimeras, radioresistant and, likely, nonhematopoietic cells were the main source of IFN, but mda5 was required in both marrow–derived and radioresistant host cells for adaptive responses. Therefore, the adjuvant action of poly IC requires a widespread innate type I IFN response that directly links antigen presentation by DCs to adaptive immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathogen Recognition and Innate Immunity
Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,952
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses
Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu, S., Jung, A., Kawai, T., Ishii, K. J., et al. (2006) · Nature · doi:10.1038/nature04734 · Cited by 3,888 · cited 2×
“helicase MDA5, resulting in activation of IRF-3 and representing a major pathway for the production of type I IFNs in a TLR-independent fashion (Kato et al., 2006).”
BackgroundMethodCloning of a new cytokine that induces IFN-γ production by T cells
Okamura, H., Tsutsui, H., Komatsu, T., Yutsudo, M., Hakura, A., Tanimoto, T., Torigoe, K., Okura, T., Nukada, Y., Hattori, K., et al. (1995) · Nature · doi:10.1038/378088a0 · Cited by 2,600
Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo
Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M., Ravetch, J. V., Steinman, R. M., & Nussenzweig, M. C. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.769 · Cited by 1,848
Self-citationThe roles of TLRs, RLRs and NLRs in pathogen recognition
Kawai, T., & Akira, S. (2009) · International Immunology · doi:10.1093/intimm/dxp017 · Cited by 1,670
Natural adjuvants: Endogenous activators of dendritic cells
Gallucci, S., Lolkema, M., & Matzinger, P. (1999) · Nature Medicine · doi:10.1038/15200 · Cited by 1,602
Differential Antigen Processing by Dendritic Cell Subsets in Vivo
Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C., Liu, K., Lee, H.-W., Park, C. G., et al. (2007) · Science · doi:10.1126/science.1136080 · Cited by 1,455
Self-citationCell Type-Specific Involvement of RIG-I in Antiviral Response
Kato, H., Sato, S., Yoneyama, M., Yamamoto, M., Uematsu, S., Matsui, K., Tsujimura, T., Takeda, K., Fujita, T., Takeuchi, O., et al. (2005) · Immunity · doi:10.1016/j.immuni.2005.04.010 · Cited by 1,368
Induced recruitment of NK cells to lymph nodes provides IFN-γ for TH1 priming
Martín-Fontecha, A., Thomsen, L. L., Brett, S., Gerard, C., Lipp, M., Lanzavecchia, A., & Sallusto, F. (2004) · Nature Immunology · doi:10.1038/ni1138 · Cited by 1,353
Cited by
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity
Kawai, T., & Akira, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.05.006 · Cited by 3,658
“Furthermore, the recognition of poly(I:C) by MDA5 expressed by DCs, monocytes, and stromal cells and the induction of type I IFN are required to support Th1 cell responses (Longhi et al., 2009).”
BackgroundPathogen Recognition by the Innate Immune System
Kumar, H., Kawai, T., & Akira, S. (2011) · International Reviews of Immunology · doi:10.3109/08830185.2010.529976 · Cited by 2,257
Regulation of Adaptive Immunity by the Innate Immune System
Iwasaki, A., & Medzhitov, R. (2010) · Science · doi:10.1126/science.1183021 · Cited by 2,157
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,924
Decisions About Dendritic Cells: Past, Present, and Future
Steinman, R. M. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-100311-102839 · Cited by 1,274
Self-citationSalmon, H., Idoyaga, J., Rahman, A., Leboeuf, M., Remark, R., Jordan, S., Casanova-Acebes, M., Khudoynazarova, M., Agudo, J., Tung, N., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.03.012 · Cited by 1,201
Self-citationType I interferon is selectively required by dendritic cells for immune rejection of tumors
Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081
Vaccine adjuvants: mechanisms and platforms
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01557-7 · Cited by 1,020
Deciphering the transcriptional network of the dendritic cell lineage
the Immunological Genome Consortium, Miller, J. C., Brown, B. D., Shay, T., Gautier, E. L., Jojic, V., Cohain, A., Pandey, G., Leboeuf, M., Elpek, K. G., et al. (2012) · Nature Immunology · doi:10.1038/ni.2370 · Cited by 781
Cabeza-Cabrerizo, M., Cardoso, A., Minutti, C. M., Pereira da Costa, M., & Reis e Sousa, C. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-061020-053707 · Cited by 757
Carroll, E. C., Jin, L., Mori, A., Muñoz-Wolf, N., Oleszycka, E., Moran, H. B. T., Mansouri, S., McEntee, C. P., Lambe, E., Agger, E. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.004 · Cited by 596
Unravelling mononuclear phagocyte heterogeneity
Geissmann, F., Gordon, S., Hume, D. A., Mowat, A. M., & Randolph, G. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2784 · Cited by 529
Ganal, S. C., Sanos, S. L., Kallfass, C., Oberle, K., Johner, C., Kirschning, C., Lienenklaus, S., Weiss, S., Staeheli, P., Aichele, P., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.05.020 · Cited by 484
Regulation of antiviral T cell responses by type I interferons
Crouse, J., Kalinke, U., & Oxenius, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3806 · Cited by 479
Nancy, P., Tagliani, E., Tay, C.-S., Asp, P., Levy, D. E., & Erlebacher, A. (2012) · Science · doi:10.1126/science.1220030 · Cited by 429
Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination
Desmet, C. J., & Ishii, K. J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3247 · Cited by 392
Shah, P. S., Link, N., Jang, G. M., Sharp, P. P., Zhu, T., Swaney, D. L., Johnson, J. R., Von Dollen, J., Ramage, H. R., Satkamp, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.028 · Cited by 380
Dendritic Cell and Macrophage Heterogeneity In Vivo
Hashimoto, D., Miller, J., & Merad, M. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.007 · Cited by 368
Dhodapkar, M. V., Sznol, M., Zhao, B., Wang, D., Carvajal, R. D., Keohan, M. L., Chuang, E., Sanborn, R. E., Lutzky, J., Powderly, J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008068 · Cited by 365
Three decades of messenger RNA vaccine development
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100766 · Cited by 342
Adaptive immune responses to primary and secondary dengue virus infections
St. John, A. L., & Rathore, A. P. S. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0123-x · Cited by 327
An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives
Facciolà, A., Visalli, G., Laganà, A., & Di Pietro, A. (2022) · Vaccines · doi:10.3390/vaccines10050819 · Cited by 316
Antonelli, L. R. V., Gigliotti Rothfuchs, A., Gonçalves, R., Roffê, E., Cheever, A. W., Bafica, A., Salazar, A. M., Feng, C. G., & Sher, A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40817 · Cited by 292
Self-citationIdoyaga, J., Lubkin, A., Fiorese, C., Lahoud, M. H., Caminschi, I., Huang, Y., Rodriguez, A., Clausen, B. E., Park, C. G., Trumpfheller, C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019547108 · Cited by 287
Self-citationAdjuvants: Classification,Modus Operandi, and Licensing
Apostólico, J. D. S., Lunardelli, V. A. S., Coirada, F. C., Boscardin, S. B., & Rosa, D. S. (2016) · Journal of Immunology Research · doi:10.1155/2016/1459394 · Cited by 287
Mouse CD8α+ DCs and human BDCA3+ DCs are major producers of IFN-λ in response to poly IC
Lauterbach, H., Bathke, B., Gilles, S., Traidl-Hoffmann, C., Luber, C. A., Fejer, G., Freudenberg, M. A., Davey, G. M., Vremec, D., Kallies, A., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092720 · Cited by 278
Caskey, M., Lefebvre, F., Filali-Mouhim, A., Cameron, M. J., Goulet, J.-P., Haddad, E. K., Breton, G., Trumpfheller, C., Pollak, S., Shimeliovich, I., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20111171 · Cited by 271
Self-citationInduction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination
McElrath, M. J., & Haynes, B. F. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.011 · Cited by 270
Type I interferons: crucial participants in disease amplification in autoimmunity
Hall, J. C., & Rosen, A. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.237 · Cited by 265
STING activation in cancer immunotherapy
Su, T., Zhang, Y., Valerie, K., Wang, X.-Y., Lin, S., & Zhu, G. (2019) · Theranostics · doi:10.7150/thno.37574 · Cited by 256
Pollard, C., Rejman, J., De Haes, W., Verrier, B., Van Gulck, E., Naessens, T., De Smedt, S., Bogaert, P., Grooten, J., Vanham, G., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.202 · Cited by 248
Minnaert, A.-K., Vanluchene, H., Verbeke, R., Lentacker, I., De Smedt, S. C., Raemdonck, K., Sanders, N. N., & Remaut, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113900 · Cited by 157
Type I interferons and dendritic cells in cancer immunotherapy
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.06.001 · Cited by 124
Zou, J., Kawai, T., Tsuchida, T., Kozaki, T., Tanaka, H., Shin, K.-S., Kumar, H., & Akira, S. (2013) · Immunity · doi:10.1016/j.immuni.2012.12.007 · Cited by 103
“Type I IFN was reported to accelerate DC maturation and cause Th1 cell polarization during virus infection or the administration of poly IC (Longhi et al., 2009), and IPS-1 is essential for type I IFN production in vivo following poly IC administration.”
BackgroundDiscovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor
Thomson, D. W., Poeckel, D., Zinn, N., Rau, C., Strohmer, K., Wagner, A. J., Graves, A. P., Perrin, J., Bantscheff, M., Duempelfeld, B., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00027 · Cited by 103
Type I interferons and endoplasmic reticulum stress in health and disease
(2020) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.10.004 · Cited by 83
“Additionally, type I IFNs are decisive for the maturation and differentiation of assorted innate immune cells (Longhi et al., 2009; Nardelli et al., 2002) .”
IRF8 and IRF3 cooperatively regulate rapid interferon-β induction in human blood monocytes
Li, P., Wong, J. J.-Y., Sum, C., Sin, W.-X., Ng, K.-Q., Koh, M. B. C., & Chin, K.-C. (2011) · Blood · doi:10.1182/blood-2010-07-294272 · Cited by 71
Roberts, B. J., Dragon, J. A., Moussawi, M., & Huber, S. A. (2012) · Biology of Sex Differences · doi:10.1186/2042-6410-3-25 · Cited by 54
Metadata
- Authors
- Longhi, M. P., Trumpfheller, C., Idoyaga, J., Caskey, M., Matos, I., Kluger, C., Salazar, A. M., Colonna, M., & Steinman, R. M.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2009-06-29
- Volume
- 206
- Issue
- 7
- Pages
- 1589-1602
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2156313733
- Cited by
- 663
- References
- 85
- FWCI
- 24.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.